Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Rozsa, Csilla; Grammond, Pierre; Alroughani, Raed; Duquette, Pierre; Girard, Marc; Pucci, Eugenio; Lechner-Scott, Jeannette; Slee, Mark; Fernandez-Bolanos, Ricardo; Grand'Maison, Francois; Hupperts, Raymond; Verheul, Freek; Hodgkinson, Suzanne; Oreja-Guevara, Celia; Spitaleri, Daniele; Barnett, Michael; TERZİ, MURAT; Bergamaschi, Roberto; McCombe, Pamela; Sanchez-Menoyo, Jose; Simo, Magdolna; Csepany, Tunde; Rum, Gabor; BOZ, CAVİT; Havrdova, Eva; Butzkueven, Helmut

doi:10.1002/ana.24339

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., ...Daha Fazla

ANNALS OF NEUROLOGY, cilt.77, sa.3, ss.425-435, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 77 Sayı: 3
Basım Tarihi: 2015
Doi Numarası: 10.1002/ana.24339
Dergi Adı: ANNALS OF NEUROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.425-435
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.